139 related articles for article (PubMed ID: 38161200)
1. Defining the Biology of Estrogen Receptor-Low-Positive Breast Cancer.
Higgins T; Kantor O; Harrison B; Giordano J; McGrath M; Burstein HJ; Schnitt SJ; Rahman T; Vora H; Garrido-Castro A; Tolaney SM; Meric-Bernstam F; King TA; Mittendorf EA
Ann Surg Oncol; 2024 Apr; 31(4):2244-2252. PubMed ID: 38161200
[TBL] [Abstract][Full Text] [Related]
2. Utility of Oncotype DX score in clinical management for T1 estrogen receptor positive, HER2 negative, and lymph node negative breast cancer.
Nguyen TTA; Postlewait LM; Zhang C; Meisel JL; O'Regan R; Badve S; Kalinsky K; Li X
Breast Cancer Res Treat; 2022 Apr; 192(3):509-516. PubMed ID: 35084624
[TBL] [Abstract][Full Text] [Related]
3. Breast carcinoma with an Oncotype Dx recurrence score <18: Rate of distant metastases in a large series with clinical follow-up.
Wen HY; Krystel-Whittemore M; Patil S; Pareja F; Bowser ZL; Dickler MN; Norton L; Morrow M; Hudis CA; Brogi E
Cancer; 2017 Jan; 123(1):131-137. PubMed ID: 27526056
[TBL] [Abstract][Full Text] [Related]
4. Is oncotype DX recurrence score (RS) of prognostic value once HER2-positive and. low-ER expression patients are removed?
Milburn M; Rosman M; Mylander C; Tafra L
Breast J; 2013; 19(4):357-64. PubMed ID: 23701403
[TBL] [Abstract][Full Text] [Related]
5. Comparison of Estrogen receptors, Progesterone receptors and HER2-neu immunohistochemistry results in breast cancer with those of Oncotype Dx.
Sughayer MA; Alhassoon S; Sughayer HM
Ann Diagn Pathol; 2020 Aug; 47():151556. PubMed ID: 32592992
[TBL] [Abstract][Full Text] [Related]
6. Genomic profiling of breast cancer in African-American women using MammaPrint.
Nunes RA; Wray L; Mete M; Herbolsheimer P; Smith KL; Bijelic L; Boisvert ME; Swain SM
Breast Cancer Res Treat; 2016 Oct; 159(3):481-8. PubMed ID: 27568021
[TBL] [Abstract][Full Text] [Related]
7. Agreement in risk prediction between the 21-gene recurrence score assay (Oncotype DX®) and the PAM50 breast cancer intrinsic Classifier™ in early-stage estrogen receptor-positive breast cancer.
Kelly CM; Bernard PS; Krishnamurthy S; Wang B; Ebbert MT; Bastien RR; Boucher KM; Young E; Iwamoto T; Pusztai L
Oncologist; 2012; 17(4):492-8. PubMed ID: 22418568
[TBL] [Abstract][Full Text] [Related]
8. Association between partial-volume corrected SUVmax and Oncotype DX recurrence score in early-stage, ER-positive/HER2-negative invasive breast cancer.
Lee SH; Ha S; An HJ; Lee JS; Han W; Im SA; Ryu HS; Kim WH; Chang JM; Cho N; Moon WK; Cheon GJ
Eur J Nucl Med Mol Imaging; 2016 Aug; 43(9):1574-84. PubMed ID: 27209424
[TBL] [Abstract][Full Text] [Related]
9. The Prognostic Significance of the Oncotype DX Recurrence Score in T
Wang M; Wu K; Zhang P; Zhang M; Ding A; Chen H
Ann Surg Oncol; 2019 May; 26(5):1227-1235. PubMed ID: 30456680
[TBL] [Abstract][Full Text] [Related]
10. Association between Oncotype DX recurrence score and dynamic contrast-enhanced MRI features in patients with estrogen receptor-positive HER2-negative invasive breast cancer.
Kim HJ; Choi WJ; Kim HH; Cha JH; Shin HJ; Chae EY
Clin Imaging; 2021 Jul; 75():131-137. PubMed ID: 33548871
[TBL] [Abstract][Full Text] [Related]
11. Breast carcinoma with 21-gene recurrence score lower than 18: rate of locoregional recurrence in a large series with clinical follow-up.
Turashvili G; Brogi E; Morrow M; Dickler M; Norton L; Hudis C; Wen HY
BMC Cancer; 2018 Jan; 18(1):42. PubMed ID: 29304773
[TBL] [Abstract][Full Text] [Related]
12. Implications of the 21-gene recurrence score assay (Oncotype DX) on adjuvant treatment decisions in ER-positive early-stage breast cancer patients: experience of Kuwait Cancer Control Center.
Fayaz S; Eissa HE; Demian GA
J Egypt Natl Canc Inst; 2020 Mar; 32(1):13. PubMed ID: 32372329
[TBL] [Abstract][Full Text] [Related]
13. Selection of neoadjuvant treatment based on the 21-GENE test results in luminal breast cancer.
Morales Murillo S; Gasol Cudos A; Veas Rodriguez J; Canosa Morales C; Melé Olivé J; Vilardell Villellas F; Sanchez Guzman DR; Iglesias Martínez E; Salud Salvia A
Breast; 2021 Apr; 56():35-41. PubMed ID: 33601299
[TBL] [Abstract][Full Text] [Related]
14. The Utility of the Oncotype DX Test for Breast Cancer Patients in an Australian Multidisciplinary Setting.
Choi JDW; Hughes TMD; Marx G; Boyages J; Rutovitz J; Hasovits C; Parasyn A; Edirimanne S; Ngui NK
Breast J; 2022; 2022():1199245. PubMed ID: 35711899
[TBL] [Abstract][Full Text] [Related]
15. Genomic Landscape and Endocrine-Resistant Subgroup in Estrogen Receptor-Positive, Progesterone Receptor-Negative, and HER2-Negative Breast Cancer.
Liu XY; Ma D; Xu XE; Jin X; Yu KD; Jiang YZ; Shao ZM
Theranostics; 2018; 8(22):6386-6399. PubMed ID: 30613307
[TBL] [Abstract][Full Text] [Related]
16. Oncotype DX Breast Cancer recurrence score resists inter-assay reproducibility with RT
Schildgen V; Warm M; Brockmann M; Schildgen O
Sci Rep; 2019 Dec; 9(1):20266. PubMed ID: 31889145
[TBL] [Abstract][Full Text] [Related]
17. Molecular Characterization of HER2-Low Invasive Breast Carcinoma by Quantitative RT-PCR Using Oncotype DX Assay.
Lin HK; Can T; Kahn A; Flannery CA; Hoag J; Akkunuri A; Bailey H; Baehner R; Pusztai L; Rozenblit M
Oncologist; 2023 Oct; 28(10):e973-e976. PubMed ID: 37656608
[TBL] [Abstract][Full Text] [Related]
18. The Role of Oncotype DX
Pardo JA; Fan B; Mele A; Serres S; Valero MG; Emhoff I; Alapati A; James TA
Ann Surg Oncol; 2021 Mar; 28(3):1320-1325. PubMed ID: 33393046
[TBL] [Abstract][Full Text] [Related]
19. Prognostic Impact of the 21-Gene Recurrence Score Assay Among Young Women With Node-Negative and Node-Positive ER-Positive/HER2-Negative Breast Cancer.
Poorvu PD; Gelber SI; Rosenberg SM; Ruddy KJ; Tamimi RM; Collins LC; Peppercorn J; Schapira L; Borges VF; Come SE; Warner E; Jakubowski DM; Russell C; Winer EP; Partridge AH
J Clin Oncol; 2020 Mar; 38(7):725-733. PubMed ID: 31809240
[TBL] [Abstract][Full Text] [Related]
20. Lymph Node Status in Breast Cancer Does Not Predict Tumor Biology.
Bello DM; Russell C; McCullough D; Tierno M; Morrow M
Ann Surg Oncol; 2018 Oct; 25(10):2884-2889. PubMed ID: 29968028
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
